Bictegravir/ Emtricitabine/ Tenofovir

• Tablet:
  • 50mg/200mg/25mg

• Can be taken without regards to meals

Bictegravir: Integrase strand transfer inhibitor (INSTI). It inhibits HIV-1 replication by blocking the strand transfer step of viral DNA integration into the host genome. Novel INSTI since it can be dosed once daily without boosting

Emtricitabine: NRTI. Cytosine analog phosphorylated to emtricitabine 5′-triphosphate causing inhibition of HIV and RNA dependent DNA polymerase

Tenofovir: NRTI. It inhibits HIV-1 RT by competing with the natural substrate deoxyadenosine 5′-triphosphate and, after incorporation into DNA, by DNA chain termination

 

• Diarrhea
• Headache
• Fatigue
• Hyperbilirubinemia
• CK elevated
• Abnormal dreams
• Dizziness
• Insomnia
• Hypercholesterolemia
• Hyperamylasemia
• Neutropenia
• LFTs elevated
• Nausea
• Vomiting
• Depression
• Rash
• Dyspepsia
• Abdominal pain
• Asthenia
• Cr incr.
• Bone density loss
• Arthralgia
• Myalgia
• Cough
• Paresthesia
• Peripheral neuropathy
• Palmar-plantar hyperpigmentation
• Hypertriglyceridemia
• Hematuria
• Hyperglycemia
• Glycosuria
• Rhinitis
• Flatulence
• Weight gain

• Hypersensitivity to drug or ingredient
• Hemodialysis (treatment-naive patients)

WARNING

• Severe acute exacerbations of hepatitis B reported in patients co-infected with HIV-1 and HBV and have discontinued products containing emtricitabine and/or tenofovir disoproxil fumarate (TDF)

• Dofetilide
• Elvitegravir/cobicistat/emtricitabine/tenofovir DF
• Fezolinetant
• Lamivudine
• Rifampin
• Cidofovir
• Phenobarbital
• Phenytoin
• Carbamazepine